Boston Scientific Corporation $BSX Shares Sold by Yousif Capital Management LLC

Key Points

• Yousif Capital Management LLC reduced its holdings in Boston Scientific Corporation by 1.9%, owning 224,621 shares valued at approximately $24.1 million after selling 4,360 shares in the second quarter.
• Analysts have recently upgraded Boston Scientific's stock, with Barclays raising its price target from $133 to $136 and maintaining an "overweight" rating, reflecting a positive outlook for the company.
• Insider trading activity has seen significant sales, with EVP Arthur C. Butcher selling 17,313 shares at an average price of $104.63, indicating a 42.32% decrease in ownership post-transaction.

Yousif Capital Management LLC lessened its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 1.9% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 224,621 shares of the medical equipment provider's stock after selling 4,360 shares during the period. Yousif Capital Management LLC's holdings in Boston Scientific were worth $24,127,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. GAMMA Investing LLC increased its stake in Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider's stock valued at $3,167,000 after buying an additional 3,932 shares during the period. MRA Advisory Group purchased a new position in Boston Scientific in the 2nd quarter valued at about $273,000. Bank of New Hampshire lifted its holdings in shares of Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider's stock worth $2,119,000 after acquiring an additional 16,699 shares during the period. NS Partners Ltd raised its stake in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock valued at $37,143,000 after acquiring an additional 5,704 shares during the period. Finally, New England Research & Management Inc. purchased a new position in shares of Boston Scientific in the 2nd quarter valued at $1,133,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BSX. Barclays raised their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. Wall Street Zen upgraded shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. UBS Group boosted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Finally, Erste Group Bank cut Boston Scientific from a "buy" rating to a "hold" rating in a research note on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Boston Scientific presently has an average rating of "Buy" and a consensus price target of $120.71.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 174,214 shares of company stock worth $17,972,457. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Performance

Boston Scientific stock opened at $95.41 on Monday. The stock has a fifty day moving average price of $101.98 and a two-hundred day moving average price of $101.87. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The firm has a market capitalization of $141.38 billion, a P/E ratio of 56.79, a P/E/G ratio of 2.30 and a beta of 0.61. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.